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Abstract
Background: Tumor cells adapt to endoplasmic reticulum (ER) stress through a set of conserved intracellular
pathways, as part of a process termed the unfolded protein response (UPR). The expression of UPR genes/proteins
correlates with increasing progression and poor clinical outcome of several tumor types, including prostate cancer.
UPR signaling can activate NF-B, a master regulator of transcription of pro-inflammatory, tumorigenic cytokines.
Previous studies have shown that Lipocalin 2 (Lcn2) is upregulated in several epithelial cancers, including prostate
cancer, and recently Lcn2 was implicated as a key mediator of breast cancer progression. Here, we hypothesize
that the tumor cell UPR regulates Lcn2 production.
Methods: We interrogated Lcn2 regulation in murine and human prostate cancer cells undergoing
pharmacological and physiological ER stress, and tested UPR and NF-B dependence by using pharmacological
inhibitors of these signaling pathways.
Results: Induction of ER stress using thapsigargin (Tg), a canonical pharmacologic ER stress inducer, or via glucose
deprivation, a physiologic ER stressor present in the tumor microenvironment, upregulates LCN2 production in
murine and human prostate cancer cells. Inhibition of the UPR using 4-phenylbutyric acid (PBA) dramatically
decreases Lcn2 transcription and translation. Inhibition of NF-B in prostate cancer cells undergoing Tg-mediated
ER stress by BAY 11-7082 abrogates Lcn2 upregulation.
Conclusions: We conclude that the UPR activates Lcn2 production in prostate cancer cells in an NF-B-dependent
manner. Our results imply that the observed upregulation of Lipocalin 2 in various types of cancer cells may be the
direct consequence of concomitant UPR activation, and that the ER stress/Lipocalin 2 axis is a potential new target
for intervention in cancer progression.
Background
Lipocalin 2 (Lcn2), otherwise known as neutrophil gela-
tinase-associated lipocalin (NGAL), is upregulated in
several solid cancers, and has been shown to facilitate
tumor progression. Yang et al [1] linked the elevated
LCN2 levels found in breast cancer with increased
tumor progression and metastasis and revealed its direct
role in facilitating the epithelial-to-mesenchymal transi-
tion (EMT) in breast cancer cells. Importantly, a Lcn2-
deficient mouse model of spontaneous breast cancer
showed a decreased rate of cancer progression [2,3].
However, the regulation and function of Lcn2 in epithe-
lial cancers remain unknown.
Lcn2 is a ligand for matrix metalloproteinase 9
(MMP9) in human neutrophils [4] and has innate
immune function through the prevention of iron scaven-
ging by bacterial siderophores [5]. Lipocalin 2 also binds
a mammalian siderophore and traffics iron in mamma-
lian cells [6-8]. The family of lipocalins, and particularly
Lcn2, has been considered a marker of inflammatory
processes such as obesity, atherosclerosis, and asthma
[9]. Furthermore, NF-B, a master regulator of
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inflammation, drives Lcn2 transcription in malignant
and untransformed cells [2,10,11].
The tumor microenvironment differs markedly from
that of normal tissues. Most notably, tumors lack a well-
developed blood supply, which leads to decreased nutri-
ent supply, low pH, and hypoxia. Compounding these
extrinsic noxae are tumor-intrinsic stressors, which
include oxidative stress, aberrant protein folding and
glycosylation, viral infection, and defects in calcium
homeostasis [12]. When un/misfolded proteins accumu-
late within the endoplasmic reticulum (ER) lumen due
to tumor-intrinsic and extrinsic stressors, tumor cells
experience ER stress. Like all eukaryotic cells, tumor
cells adapt to ER stress by signaling through a conserved
set of intracellular pathways known collectively as the
unfolded protein response (UPR) [13]. The UPR is
initiated by the ER chaperone molecule, Grp78, which,
under conditions of ER stress, disassociates from three
ER membrane-bound sensors (IRE1a, ATF6, and
PERK), causing their activation. Downstream signaling
cascades ameliorate ER stress via several mechanisms,
including selective translation inhibition and upregula-
tion of genes that encode enzymes that aid in protein
folding, maturation, and degradation [14]. Involved in
this homeostatic/regulatory cascade are two target
genes, Gadd34 and Chop, that are associated with trans-
lational recovery and apoptosis, respectively [13].
Prostate cancer is the most prevalent cancer in men.
Prostate cancer cells often gain resistance to early thera-
peutic interventions, and relapse is common (> 40%)
[15]. Recently, the ability to mount the UPR has been
linked to prostate tumorigenesis and cancer progression.
For example, conditional deletion of Grp78 in the pros-
tates of Pten-deficient mice abrogates prostate tumori-
genesis [16]. Additionally, human prostate cancer cells
express significantly more GRP78 than their benign
counterparts, and increasing GRP78 expression corre-
lates with recurrence and poor survival [17].
With the exception of work showing that the LCN2/
MMP9 complex is more likely to be found in the urine of
prostate cancer patients than controls [18], little is
known about LCN2 in prostate cancer. Additionally,
while ER stress and Lcn2 are both associated with cancer
tumorigenesis, progression, and poor clinical outcome, to
date there has been no mechanistic explanation for these
correlations. We used an in vitro model of ER stress to
test the hypothesis that ER stress and Lcn2 upregulation
are causally linked in prostate cancer cells, as a first step
in an effort to elucidate the broad role of constitutive ER
stress in cancer cells. We demonstrate that the ER stress
response in murine and human prostate cancer cells
drives the production of Lcn2 in an NF-B-dependent
manner, and that diminishing the UPR dramatically
decreases Lcn2 transcription and translation.
Methods
Cell Culture
TRAMP-C1 (TC1) cells were originally obtained from Dr.
Andrew Weinberg (Oregon Health Science University).
LNCaP and PC3 cells were purchased from American
Type Culture Collection (ATCC). All lines were grown in
complete RPMI-1640 medium supplemented with 10%
heat-inactivated fetal calf serum (HyClone) and tested
negative for mycoplasma (Lonza). All three cell lines were
induced to undergo ER stress by the addition of 300 nM
thapsigargin (Tg) (Alexis Biochemicals/Enzo Life Sciences,
Plymouth, PA), 5 μg/mL of tunicamycin (Tun) (Sigma), or
culture in medium lacking glucose, for indicated time
points. Control cells were similarly treated with an equal
volume of vehicle (100% ethanol or DMSO).
Generation of TC1.pNGL and ER Stress Response/NF-B
Inhibition
The pNGL plasmid was graciously provided by Dr. T.
Blackwell (Vanderbilt University, Nashville, TN). The
pNGL plasmid contains a GFP/luciferase fusion gene
driven by a minimal herpesvirus thymidine kinase pro-
moter and eight decameric NF-B binding sites
(GGGGACTTTCC). TOP10 competent cells (Invitro-
gen) were transformed and selected on ampicillin-con-
taining agar. Purified pNGL plasmid was obtained using
the Wizard MiniPrep kit (Promega), and concentration
and purity determined on a NanoDrop spectrophot-
ometer (Thermo Scientific). TC1 cells were transfected
in a 24 well plate with 2 μg DNA using the JetPEI
reagent (Polyplus). Cells were initially selected in med-
ium containing 800 μg/mL G418, and successful trans-
fectants were maintained in 500 μg/mL G418.
For initial NF-B kinetics experiments, cells were trea-
ted with Tg (300 nM) or vehicle (100% ethanol), or with
100 ng/mL LPS (Sigma) for the indicated time points. In
ER stress response inhibition experiments, TC1.pNGL
cells were treated for 8 h with Tg (300 nM) in the pre-
sence of 10 mM 4-phenylbutyric acid (PBA) (Sigma). In
NF-B inhibition experiments, TC1.pNGL cells (2.5 ×
105) were co-treated for 8 h with Tg (300 nM) and 25
μM Bay 11-7082 (EMD Chemicals). Live cells (7-AAD-)
were gated and analyzed for NF-B-driven EGFP repor-
ter on a BDFacscalibur (BD Biosciences). Data was
acquired and analyzed using BD CellQuest Pro and
FlowJo (Tree Star) software.
Quantitative RT-PCR
RNA was isolated from cells using the Nucleospin RNA
II Kit (Macherey-Nagel). Concentration and purity of
RNA was determined by analysis on a NanoDrop spec-
trophotometer (Thermo Scientific). cDNA was gener-
ated using the High Capacity cDNA Synthesis kit
(Applied Biosystems) and quantitative PCR was
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performed on an ABI StepOne system using TaqMan
reagents (Applied Biosystems) for 50 cycles. Target gene
expression was normalized to b-actin, and analyzed
using the -ΔΔCt relative quantification method. Results
are expressed as fold change relative to the vehicle-trea-
ted control cells, whose gene expression profile did not
differ from untreated cells. Validated FAM-labeled
mouse Il-23a (Mm00518984_m1), Il-6 (Mm9999
9064_m1), Ddit3 (Mm01135937_g1), Myd116 (Mm00
435119_m1), Hspa5 (Mm00517691_m1), Lcn2
(Mm01324472_g1) and VIC-labeled mouse b-actin Taq-
Man primer/probe sets (Applied Biosystems) were used
to analyze TC1 cDNA. Validated FAM-labeled human
IL-23A (Hs00372324_m1), IL-6 (Hs0098639_m1),
HSPA5 (Hs99999174_m1), LCN2 (Hs00194353_m1), and
VIC-labeled human b-ACTIN TaqMan primer/probe
sets (Applied Biosystems) were used to analyze PC3 and
LNCaP cDNA. Custom primers for human CHOP and
GADD34 were synthesized (Applied Biosystems) using
gene sequences with NCBI accession numbers
NM_004083 and NM_014330, respectively. qPCR data
was analyzed and statistical analysis performed using
ABI StepOne software and GraphPad Prism software.
Western Blot Analysis
After treatment, TC1 cells were washed in ice-cold PBS
and re-suspended in cold lysis buffer containing 1% Tri-
ton X-100, 150 mM NaCl and 50 mM Tris-HCl, pH 8.
Cell lysates were kept for 10 min on ice followed by
centrifugation at 20,000 g for 10 min at 4°C. Cell lysates
were then boiled at 95°C for 5 minutes. Total protein
(90 μg) was then electrophoresed on a 12.5% SDS-
PAGE gel and transferred overnight onto nitrocellulose
paper. Western blotting was performed using a goat
polyclonal anti-mouse Lipocalin-2/NGAL antibody
(R&D Systems, MN, USA) and revealed using an HRP-
conjugated donkey antibody to goat IgG (Santa Cruz
Biotechnology, Santa Cruz, CA). Bands were visualized
using SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Scientific, IL USA).
Results
The transcriptional kinetics of Lcn2 follows that of
the UPR in murine prostate cancer cells
We first suspected a link between Lcn2 and tumor cell
ER stress when we found that among the genes most
upregulated in murine A20 lymphoma cells following
treatment with thapsigargin (Tg), a canonical inducer of
ER stress, was Lcn2 [19] (Additional File 1 Table S1).
Because of this observation, we proceeded to investigate
the effect of ER stress on murine prostate cancer cells
from TRAMP mice, a transgenic model of spontaneous
prostate adenocarcinoma that recapitulates the progres-
sion, genetic changes, and histology of human prostate
cancer [20]. TRAMP C1 (TC1) cells are derived from
TRAMP mice and form tumors when injected orthoto-
pically [21]. Tg-treated TC1 cells upregulated Lcn2 tran-
scription following kinetics that closely match those of
three UPR genes, Grp78, Gadd34, and Chop, peaking
between 12 and 18 hours after Tg treatment (Figure
1A). Physiological ER stress induced in TC1 via glucose
deprivation also caused Lcn2 transcriptional upregula-
tion (Figure 1B). We confirmed that cancer cells of
diverse histological origin, including murine melanoma
and lung carcinoma, and human colon, ovarian, and
breast carcinoma, upregulate LCN2 transcription under
ER stress (Additional File 2 Fig. S1). Pharmacological ER
Figure 1 Lcn2 and pro-inflammatory cytokine gene
transcription in murine prostate cancer cells follows the
kinetics of the UPR. (A) TC1 cells were treated with Tg (300 nM)
for the indicated times, after which mRNA was isolated and
analyzed by RT-qPCR for markers of UPR activation and Lcn2
transcription. Data columns indicate the relative quantification (RQ),
or fold difference, in transcript level between Tg- and vehicle-
treated TC1 cells. A representative experiment of at least three
independent experiments per time point is shown. (B) TC1 cells
were cultured in RPMI lacking glucose for 24 h and analyzed by RT-
qPCR for markers of UPR activation and Lcn2 transcription. Error bars
represent SEM of 2 biological replicates representative of at least 3
independent experiments. Statistical analysis was performed using
an unpaired two-tailed t test (**p < 0.01; ***p < 0.001).
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stress also induces LCN2 transcription in non-neoplastic
cells, although more robustly in cells of epithelial versus
myeloid origin (Additional File 3 Fig. S2). These results
suggest that Lcn2 transcription may lie downstream of
UPR activation.
Lcn2 upregulation is UPR-mediated and NF-B-dependent
We and others have suggested that the response to ER
stress can lead to activation of an inflammatory tran-
scriptional program [14,19]. Lcn2 transcription has
already been shown to be dependent on NF-B activa-
tion in breast and thyroid cancer cells [2,10,11] and NF-
B has been shown to bind to the Lcn2 promoter [11].
To test whether transcription of Lcn2 is associated with
activation of NF-B in prostate cancer cells, we created
a transgenic TC1 cell line, which carries an NF-B
reporter plasmid (TC1.pNGL) containing an enhanced
green fluorescent protein (EGFP)-luciferase fusion gene
[22]. Induction of ER stress in TC1.pNGL with Tg
revealed NF-B-driven fluorescence between 4 and 12
hours after treatment, with a peak at 8 hours (Figure
2A). Therefore, this result indicates that ER stress trig-
gers NF-B activation, confirming previous reports
[23,24].
Next, we probed TC1 cells using qPCR for transcrip-
tion of two pro-inflammatory cytokines, Il-6 and Il-
23p19, both of which have been implicated in tumor
progression [25,26]. We detected transcriptional upregu-
lation of these two cytokines with kinetics matching that
of the UPR genes, Grp78, Gadd34, and Chop, peaking at
18 hours after Tg exposure (Additional File 4 Fig. S3).
Thus, we found that NF-B activation directly precedes
the transcriptional activation of Lcn2 and that of pro-
inflammatory cytokines, suggesting that Lcn2 transcrip-
tion is part of an UPR-mediated inflammatory program
in prostate cancer cells.
To verify that the ER stress response is necessary for
NF-B activation and consequent cytokine and Lcn2
transcriptional upregulation, we treated TC1.pNGL cells
with 4-phenyl butyric acid (PBA), a chemical chaperone
known to reduce ER stress [27], during Tg stimulation.
PBA-treated cells displayed significant inhibition of the
UPR as indicated by decreased levels of Grp78, Gadd34
and Chop, relative to cells treated with Tg alone (Figure
2B). Notably, PBA-treated cells did not activate NF-B
in response to Tg treatment (Figure 2C) and this
resulted in a complete abrogation of ER stress-mediated
Lcn2 transcription, as well as Il-6 and Il-23p19 tran-
scription (Figure 2D). Western blotting of TC1 treated
with Tg alone or in combination with PBA verified the
UPR-specific translation of Lcn2 (Figure 2E).
To confirm that the UPR drives the transcriptional
upregulation of Lcn2 via NF-B, we treated Tg-activated
TC1.pNGL cells with BAY 11-7082, an irreversible
inhibitor of IBa phosphorylation, which results in the
down-regulation of NF-B activation [28]. At the dose
used (25 μM), BAY 11-7082 inhibited ER stress-
mediated NF-B activation by 48% (MFI Veh: 50; MFI
Bay + Tg: 61.8; MFI Tg: 72.7) (Figure 3A) with minimal
effect on the UPR and cell viability (all treatment groups
had > 99% viability) (Figure 3B). At higher concentra-
tions of Bay 11-7082, UPR-induced NF-B activation
was more greatly inhibited but cell death and confound-
ing off-target effects (e.g., UPR inhibition) were also
increased dramatically. Consistent with our prediction,
BAY 11-7082 markedly inhibited the UPR-induced tran-
scriptional upregulation of Lcn2, Il-6 and Il-23p19 (Fig-
ure 3B). Taken together, these data indicate that ER
stress in murine prostate cancer cells drives the NF-B-
dependent transcription of Lcn2 and pro-inflammatory
cytokines.
Human prostate cancer cells upregulate LCN2 and pro-
inflammatory cytokines in response to ER stress
To extend these findings to human prostate cancer, we
interrogated LCN2 activation during conditions of ER
stress in two human prostate cancer cell lines, LNCaP
and PC3. We found that LCN2 is upregulated by Tg-
induced ER stress in both cell lines, as were the pro-
inflammatory cytokines, IL-6 and IL-23p19 (Figure 4A).
LNCaP cells also upregulated LCN2, IL-6 and IL-23p19
transcription in response to treatment with tunicamycin,
another inducer of ER stress, albeit to a lower magni-
tude than cells treated with Tg (Additional File 5 Fig.
S4). Corroborating our results in TC1 cells, treatment of
LNCaP cells with PBA prevented Tg-induced LCN2, IL-
6 and IL-23p19 transcription (Figure 4B). Taken
together, these results indicate that the ER stress
response drives transcription of LCN2 and pro-inflam-
matory cytokines in human prostate cancer cells.
Discussion
Because Lcn2 is a gene found in non-neoplastic cells
that has been shown to function in the regulation of
tumor cell growth and progression [3] it fulfills the
canonical definition of a proto-oncogene [29]. Here we
establish a link between the ER stress response in pros-
tate cancer cells and Lcn2 upregulation. Evidence is also
provided that this event may be part of a larger program
of an NF-B-dependent response. Lastly, we show that
diminishing the magnitude of the UPR using a chemical
chaperone can dramatically decrease the production of
Lcn2 and tumorigenic cytokines. The present report
finds indirect corroboration in earlier studies showing
that stearoyl-CoA desaturase 1 (SCD1)-deficient mice
fed a very low-fat diet experience ER stress in the liver
concomitant with high levels of Lcn2 transcription [30],
and that IRE1a or PERK can activate NF-B [24,31],
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which itself binds the Lcn2 promoter, driving its tran-
scription [11]. Our findings are also corroborated by the
observation that the Lcn2 promoter contains binding
sites the ER stress-responsive transcription factor C/EBP
(CCAAT/enhancer-binding protein) [11,32].
The link between ER stress and cancer progression
has been previously suggested. For instance, Grp78
hemizygous (+/-) mice crossed with MMTVPyVT het-
erozygous transgenic mice display significantly decreased
tumor proliferation, survival, and angiogenesis [33].
Similarly, the inactivation of ER stress signaling by
mutations of PERK, or by a dominant-negative PERK, in
tumor cells, results in tumors that are smaller and less
aggressive than their normal counterparts when
implanted into mice [34]. Furthermore, increasing levels
of Grp78 positively correlate with solid tumor progres-
sion and poor clinical outcome [17,35]. In parallel, a
link between Lipocalin 2 and cancer has also been
reported. For instance, Lipocalin 2 is upregulated in
human cancers of several origins and, importantly, its
levels correlate with the aggressiveness of clonally-
derived murine breast cancer cell lines [2].
In light of the present findings, it is tempting to
speculate that Lipocalin 2 expression levels correlate
with tumor progression because of the concomitant
upregulation of the UPR. In the case of prostate can-
cer, it will be interesting to simultaneously analyze
other markers of prostate cancer progression, e.g.,
TMPRSS-ERG fusion events [36], to see if their pre-
sence also correlates with upregulation of Lipocalin 2.
Figure 2 ER stress-mediated Lcn2 transcription is dependent on NF-B activation in murine prostate cancer cells. (A) TC1.pNGL cells
were treated with Tg (300 nM) or vehicle control (Veh), or LPS, for the indicated times. Cells were analyzed for EGFP reporter fluorescence by
flow cytometry. Results shown are representative of 2-5 experiments. (B) TC1.pNGL cells were treated with Tg with or without 10 mM 4-
phenylbutyric acid (PBA), or vehicle only. RNA was isolated and analyzed for UPR activation by RT-qPCR. Data columns indicate the fold
difference in transcript level between drug- and vehicle-treated TC1.pNGL cells. Error bars represent SEM of 2-3 biological replicates
representative of 3 independent experiments. (C) TC1.pNGL cells were treated as in (B) and analyzed for EGFP reporter fluorescence by flow
cytometry. Cell viability of all treatment groups was > 99%. (D) TC1.pNGL cells from (B) were also analyzed for Lcn2, Il-6, and Il-23p19
transcription by RT-qPCR. Data columns indicate the fold difference in transcript level between drug- and vehicle-treated TC1.pNGL cells, and
error bars represent SEM of 2-3 biological replicates representative of 3 independent experiments. Statistical analysis was performed using an
unpaired two-tailed t test (**p < 0.01; ***p < 0.001). (E) Untreated TC1 cells (lane 1) or TC1 treated with vehicle control (lane 2), Tg (lane 3), or
Tg + PBA (lane 4), as indicated above, were analyzed for Lipocalin 2 production by Western blot.
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If our prediction turns out to be correct, we anticipate
that Lipocalin 2 could serve as a novel biomarker of
prostate cancer progression [18].
What signaling elements connect the UPR to NF-B
activation and Lipocalin 2 upregulation in cancer cells?
Fu et al. [16] demonstrated that prostate-specific
knockdown of Grp78 in Pten-null mice abrogates AKT
phosphorylation (and tumor development), and that
human prostate cancer cells under ER stress increase
AKT phosphorylation in a Grp78-dependent manner.
Recently, it was shown that inhibition of AKT phos-
phorylation and/or NF-B activation both caused
Figure 3 UPR-mediated Lcn2 transcription is NF-B dependent. (A) TC1.pNGL cells were treated for 8 h with Tg (300 nM) with or without
Bay 11-7082 (25 μM), or vehicle alone, and analyzed for EGFP reporter fluorescence by flow cytometry. Cells viability in all treatment groups was
> 99%. Results shown are representative of 3 experiments. (MFI Veh: 50; MFI Bay + Tg: 61.8; MFI Tg: 72.7) (B) RNA was isolated from cells from
(A) and analyzed for UPR activation and Lcn2, Il-6, and Il-23p19 transcription by RT-qPCR. Data columns indicate the fold difference in transcript
level between drug- and vehicle-treated TC1.pNGL cells. Error bars represent SEM of 2-3 biological replicates. Statistical analysis was performed
using an unpaired two-tailed t test (**p < 0.01; ***p < 0.001).
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downregulation of LCN2 expression in human breast
cancer cells [2]. Taken together, these findings suggest
that ER stress in cancer cells may be the primary trig-
gering event for Lipocalin 2 activation via the Grp78/
AKT/NF-B axis. The recently demonstrated efficacy of
anti-Lcn2 antibody therapy in slowing mammary tumor
growth and metastasis in mice [2] together with the
potential use of small molecules and chemical chaper-
ones to inhibit Grp78 and UPR [27,37], identifies the ER
stress-Lipocalin 2 axis as a novel target for synergistic
therapeutic intervention in several cancers, including
prostate cancer.
Conclusions
Here, we demonstrate that the UPR evoked by pharma-
cological and physiological ER stress in prostate cancer
cells can drive the transcription and translation of the
proto-oncogene, Lcn2. This process is mediated by
UPR-dependent activation of NF-B.
Additional material
Additional file 1: Table S1. Selected gene expression profiling in A20 B
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Additional file 2: Figure S1. ER stress in mouse and human neoplastic
cells evokes Lcn2 transcription.
Additional file 3: Figure S2. ER stress in non-neoplastic cells of mouse
and human origin induces Lcn2 transcription.
Additional file 4: Figure S3. ER stress in prostate cancer cells promotes
transcription of proinflammatory cytokines.
Additional file 5: Figure S4. Tunicamycin-induced ER stress activates
Lcn2 transcription in human prostate cancer cells.
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Figure 4 The ER stress response drives LCN2 transcription in
human prostate cancer cells. (A) LNCaP or PC3 cells were treated
with Tg (300 nM) for the indicated times. RNA was isolated and
analyzed for UPR activation, LCN2, Il-6, and Il-23p19 transcription by
RT-qPCR. Data columns indicate the fold difference in transcript
level between drug- and vehicle-treated, or untreated cells and
error bars represent SEM of 2 biological replicates representative of
three independent experiments. (B) LNCaP cells were treated for 18
h with Tg alone, PBA (10 mM) and Tg, or vehicle only. RNA was
isolated and analyzed for UPR activation, LCN2, IL-6, and IL-23p19
transcription by RT-qPCR. Data columns indicate the fold difference
in transcript level between drug- and vehicle-treated cells and error
bars represent SEM of 2-3 biological replicates representative of two
independent experiments. Statistical analysis was performed using
an unpaired two-tailed t test (***p < 0.001).
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